HIV/AIDS – mycolab.ai

The 2025 EQUAL Pneumocystis Score—an ECMM tool to measure QUALity in Pneumocystis pneumonia management

mycolabadmin

Pneumocystis pneumonia is a serious lung infection that affects people with weakened immune systems, including those with HIV and transplant patients. Doctors use different guidelines to diagnose and treat this infection, but these guidelines are complex and can be hard to follow consistently. Researchers created a new scoring system called the EQUAL Pneumocystis Score that helps doctors follow the best treatment recommendations by assigning points for different diagnostic tests, medications, and follow-up strategies.

Emerging Infections Network Survey of Screening for Cryptococcal Antigenemia, United States, 2024

mycolabadmin

Researchers surveyed infectious disease doctors across the United States about their use of a blood test (cryptococcal antigen screening) to detect a serious fungal infection in HIV patients before symptoms appear. Only about one-third to two-thirds of doctors regularly perform this inexpensive and accurate test, depending on the patient’s immune system status. Many doctors were unsure about the benefits and guidelines for this screening, suggesting that education and clearer guidelines could help more patients catch this dangerous infection early and receive treatment before it becomes life-threatening.

Photo Quiz: A cutaneous fungal infection with discordant biomarker results—a diagnostic challenge

mycolabadmin

This case describes a woman with advanced HIV who developed a serious fungal infection called histoplasmosis affecting her skin, lungs, and lymph nodes. Diagnosis was challenging because standard fungal blood tests came back negative, but careful examination of samples and specialized testing confirmed Histoplasma capsulatum. The patient was successfully treated with antifungal medications, highlighting the importance of not relying solely on negative tests when clinical suspicion is high.

Emerging Infections Network Survey of Screening for Cryptococcal Antigenemia, United States, 2024

mycolabadmin

This survey asked infectious disease doctors across the United States about their use of a simple blood test (cryptococcal antigen screening) for HIV patients. The test can detect a dangerous fungal infection weeks before symptoms appear, allowing for early treatment. However, the survey found that many doctors are not using this recommended test regularly, primarily because they are unsure about its benefits and are confused about screening guidelines.

Access to diagnostic testing for invasive fungal diseases and other opportunistic infections in Mexican health care centers caring for patients living with HIV

mycolabadmin

This study examined the availability of diagnostic tests for fungal and other serious infections in Mexican HIV clinics. Researchers found that most clinics, especially smaller primary care facilities, lack modern rapid testing equipment needed to quickly diagnose dangerous infections like cryptococcosis and histoplasmosis. These infections are common in people with advanced HIV and can be life-threatening, making access to rapid diagnosis crucial for treatment and survival.

Differential composition of the pulmonary microbiome in HIV-positive versus HIV-negative patients with Pneumocystis jirovecii

mycolabadmin

This study compared lung infections in HIV-positive and HIV-negative patients who both had Pneumocystis jirovecii. Researchers found that HIV-positive patients had more diverse microorganisms in their lungs, particularly viruses, yet generally did better. HIV-negative patients had fewer types of microorganisms but worse outcomes. The findings suggest that the way a person’s immune system is weakened matters more than just having many germs present.

mGem: Sepsis and antimicrobial resistance in the context of advanced HIV disease

mycolabadmin

This review examines how serious infections (sepsis) from bacteria and fungi affect people with advanced HIV disease, particularly in hospitals. The infections have become more dangerous due to antimicrobial resistance, and many cases go undiagnosed because of limited laboratory capabilities. The paper calls for better diagnostic tools and treatment strategies tailored to resource-limited settings where most advanced HIV disease cases occur.

Evaluation of Antifungal Activity Against Candida albicans Isolates From HIV-Positive Patients with Oral Candidiasis in a Major Referral Hospital, West Java, Indonesia

mycolabadmin

This study examined fungal infections in HIV-positive patients suffering from oral candidiasis (mouth thrush) in Indonesia. Researchers identified the types of Candida fungi present and tested their resistance to four common antifungal medications. Most patients had Candida albicans, and while these fungi generally responded well to newer antifungal drugs like voriconazole and fluconazole, some showed resistance, particularly to fluconazole, suggesting the need for careful testing before prescribing treatment.

John Perfect Shares Insights on Infectious Diseases, Antifungal Therapy, and Drug Resistance

mycolabadmin

This interview with Dr. John Perfect, a leading expert in fungal infections, discusses how antifungal treatments have evolved over his 48-year career. He explains that while fungal resistance is a concern, it’s less problematic than bacterial antibiotic resistance because fungi don’t spread resistance through plasmids. Dr. Perfect emphasizes the importance of newer, faster-acting antifungal drugs and combining drug therapy with immune system support to better treat serious fungal infections like cryptococcal meningitis and candidemia.

John Perfect Shares Insights on Infectious Diseases, Antifungal Therapy, and Drug Resistance

mycolabadmin

Dr. John Perfect, a leading expert in fungal infections, shares his 48 years of experience studying infectious diseases, particularly focusing on Cryptococcus and candida infections. He discusses how antifungal medications have evolved from highly toxic drugs to more effective treatments, while emphasizing the need for faster-acting drugs that require shorter treatment periods. The interview covers emerging diagnostic tools using molecular methods, the promise of combining drugs with immune-boosting therapies, and the importance of understanding how fungi survive in the human body to develop better treatments.

Research Topic: HIV/AIDS